At a glance
ClinicalIndex Comparison RecordN/AUnknown· 200 target
Drug / intervention
Relmacabtagene Autoleucelbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma
In Brief
An observational study evaluating Relmacabtagene Autoleucel for Large B-cell Lymphoma. Targeting 200 participants across 1 site.
Detailed Summary
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLarge B-cell Lymphoma
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
2023202420252026
Enrollment StartDec 2022
First PostedNov 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedNov 21, 2023
Enrollment StartDec 28, 2022
Primary CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.6 years ago
Interventions
Relmacabtagene Autoleucelbiological
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells